Compass Therapeutics's three largest insider shareholders as of April 17, 2026 are Thomas J. Schuetz (Chief Executive Officer, 6.60Mn shares), Vered Bisker-Leib (Chief Executive Officer, 3.12Mn shares), Jonathan Anderman (General Counsel, 171.00K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Thomas J. Schuetz | Chief Executive Officer | 6,603,336 | 0 | 10 Feb, 2026 |
| Vered Bisker-Leib | Chief Executive Officer | 3,124,426 | 0 | 09 Feb, 2024 |
| Jonathan Anderman | General Counsel | 171,000 | 0 | 05 Jan, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 08 Feb, 2026 | Thomas J. Schuetz | Common Stock | D | 36,687 | $6.52 | 6,603,336 | D | F |
| 09 Jan, 2026 | Thomas J. Schuetz | Common Stock | D | 46,777 | $5.35 | 6,640,023 | D | F |
| 02 Jan, 2026 | Cynthia Sirard | STOCK OPTION (RIGHT TO BUY) | A | 1,000,000 | $0.00 | 1,000,000 | D | A |
| 02 Jan, 2026 | Jonathan Anderman | Common Stock | A | 150,000 | $5.17 | 171,000 | D | A |
| 02 Jan, 2026 | Richard S Lindahl | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | Ellen Chiniara | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | Thomas J. Schuetz | Common Stock | A | 250,000 | $5.17 | 6,686,800 | D | A |
| 02 Jan, 2026 | Arjun Prasad | STOCK OPTION (RIGHT TO BUY) | A | 1,000,000 | $0.00 | 1,000,000 | D | A |
| 02 Jan, 2026 | Philip Ferneau | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | James P Boylan | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | Jonathan Anderman | Stock Option (Right to Buy) | A | 720,000 | $0.00 | 720,000 | D | A |
| 02 Jan, 2026 | Thomas J. Schuetz | Stock Option (Right to Buy) | A | 2,000,000 | $0.00 | 2,000,000 | D | A |
| 16 Nov, 2025 | Thomas J. Schuetz | Common Stock | D | 44,025 | $4.83 | 6,436,800 | D | F |
| 27 May, 2025 | Thomas J. Schuetz | Common Stock | A | 10,000 | $2.11 | 6,480,825 | D | P |
| 09 Apr, 2025 | Advisors Llc Orbimed | Common Stock | D | 3,571,428 | $1.59 | 0 | I | S |
| 07 Apr, 2025 | Jonathan Anderman | Common Stock | A | 20,000 | $1.54 | 21,000 | D | P |
| 11 Feb, 2025 | Ellen Chiniara | Stock Option (Right to Buy) | A | 40,000 | $0.00 | 40,000 | D | A |
| 11 Feb, 2025 | James P Boylan | Stock Option (Right to Buy) | A | 40,000 | $0.00 | 40,000 | D | A |
| 11 Feb, 2025 | Thomas J. Schuetz | Stock Option (Right to Buy) | A | 1,500,000 | $0.00 | 1,500,000 | D | A |
| 11 Feb, 2025 | Richard S Lindahl | Stock Option (Right to Buy) | A | 40,000 | $0.00 | 40,000 | D | A |